Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Best Practices for Cardiovascular Team-Based Care: Cardiac Heart Diseases (CHD)...
share announcement

Best Practices for Cardiovascular Team-Based Care: Cardiac Heart Diseases (CHD) Clinical Conundrum

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 2296

Special Issue Editors

Dr. Fabiana Lucà

E-Mail Website
Guest Editor
Department of Cariology, Big Metropolitan Hospital of Reggio Calabria, 89129 Reggio Calabria, Italy
Interests: atrial fibrillation; supraventricular arrhythmias; ventricular arrhythmias; sudden cardiac death (SCD); acute and chronic heart failure; ischemic heart disease; pacemaker; cardiac resynchronization therapy (CRT); implantable cardioverter defibrillator (ICD)
Special Issues, Collections and Topics in MDPI journals
Dr. Maurizio G. Abrignani

E-Mail
Guest Editor
Department of Cardiology, P.O. Sant’Antonio Abate, ASP Trapani, 91016 Erice, Italy
Interests: cardiovascular epidemiology; cardiovascular prevention; risk factors; coronary heart disease

Special Issue Information

Dear Colleagues,

Cardiac heart diseases (CHD) represent a clinical conundrum.

Team-based care uses multidisciplinary teams, health professionals, community health workers, and others.

Practical insights for physicians who cope with patients with cardiopathies should be constantly updated, addressing state-of-the-art of the entire spectrum of cardiac heart failure(HF), including HF with preserved ejection fraction (HFpEF), HF with mid-range ejection fraction (HFmEF), and HF with reduced ejection fraction (HFrEF), coronary heart diseases (CHD), complex revascularization of coronary arteries and peripheral arterial disease (PAD), and other cardiomyopathies.

This Special Issue aims to highlight best practices for managing CHD as well as the assessment of emerging new therapies, treatment options, more advanced team-based strategies, clinic workflows and protocols.

Dr. Fabiana Lucà
Dr. Maurizio G. Abrignani 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • team-based care
  • multidisciplinary teams
  • health professionals
  • heart failure(HF)
  • HFpEF
  • HFmEF
  • and HFrEF
  • coronary heart diseases (CHD)
  • revascularization
  • peripheric artery diseases (PAD)
  • cardiomyopathies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1667 KiB  
Article
Outcome of Surgery for Ischemic Mitral Regurgitation Depends on the Type and Timing of the Coronary Revascularization
by Terézia B. Andrási, Alannah C. Glück, Olfa Ben Taieb, Ildar Talipov, Nunijiati Abudureheman, Lachezar Volevski and Ion Vasiloi
J. Clin. Med. 2023, 12(9), 3182; https://doi.org/10.3390/jcm12093182 - 28 Apr 2023
Cited by 1 | Viewed by 967
Abstract
Objective: Long-term outcomes of mitral valve (MV) repair versus MV replacement for ischemic mitral regurgitation (IMR) in patients undergoing either prior (PCR) or concomitant coronary revascularization (CCR) by surgery (CABG) or intervention (PCI) are uncertain. Methods and Results: Of 446 patients receiving MV [...] Read more.
Objective: Long-term outcomes of mitral valve (MV) repair versus MV replacement for ischemic mitral regurgitation (IMR) in patients undergoing either prior (PCR) or concomitant coronary revascularization (CCR) by surgery (CABG) or intervention (PCI) are uncertain. Methods and Results: Of 446 patients receiving MV surgery for IMR between July 2006 and December 2010, 125 patients—87 CCR (69.1%) and 38 PCR (30.9%)—were eligible for inclusion in the study. Survival was higher in CCR versus PCR at long-term follow-up (78.83% vs. 57.9%, p = 0.016). The incidence of MACCE was lower in the CCR compared to PCR at both hospital discharge (34.11% vs. 63.57%, p = 0.003) and at follow-up (34.11% vs. 65.79%, p = 0.0008). Patients receiving CABG or CABG with PCI in PCR had higher mortality risks after MV surgery than CCR patients (X2 = 6.029, p = 0.014 and X2 = 6.466, p = 0.011, respectively). Whereas in the PCR group, MV repair and MV replacement achieved similar survival probability (X2 = 1.551, p = 0.213), MV repair in the CCR group led to improved survival compared to MV replacement (X2 = 3.921, p = 0.048). In MV replacement, LAD-CABG improved survival compared to LAD-PCI (U = 15,000.00, Z = −2.373 p = 0.018), and a substantial impact of arterial IMA-LAD grafting was revealed in the Cox-regression analysis (HR 0.334, CI: 0.113–0.989, p = 0.048) as opposed to venous-LAD grafting (HR 0.588, CI: 0.166–2.078, p = 0.410). Conclusion: Early treatment of IMR concomitant to coronary revascularization enhances long-term survival compared to delayed MV surgery after PCR. MV repair is not superior to MV replacement when performed late after coronary revascularization; however, MV repair leads to better survival than MV replacement when performed concomitantly with CABG with arterial LAD revascularization. Full article
(This article belongs to the Special Issue Best Practices for Cardiovascular Team-Based Care: Cardiac Heart Diseases (CHD) Clinical Conundrum)
►▼ Show Figures

Figure 1

Review

Jump to: Research

10 pages, 735 KiB  
Review
Lights and Shadows of Clinical Applications of Cardiac Scintigraphy with Bone Tracers in Suspected Amyloidosis
by Riccardo Saro, Daniela Pavan, Aldostefano Porcari, Gianfranco Sinagra and Marco Mojoli
J. Clin. Med. 2023, 12(24), 7605; https://doi.org/10.3390/jcm12247605 - 10 Dec 2023
Viewed by 900
Abstract
Radionuclide bone scintigraphy is the cornerstone of an imaging-based algorithm for accurate non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA). In patients with heart failure and suggestive echocardiographic and/or cardiac magnetic resonance imaging findings, the positive predictive value of Perugini grade 2 or 3 [...] Read more.
Radionuclide bone scintigraphy is the cornerstone of an imaging-based algorithm for accurate non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA). In patients with heart failure and suggestive echocardiographic and/or cardiac magnetic resonance imaging findings, the positive predictive value of Perugini grade 2 or 3 myocardial uptake on a radionuclide bone scan approaches 100% for the diagnosis of ATTR-CA as long as there is no biochemical evidence of a clonal dyscrasia. The technetium-labelled tracers that are currently validated for non-invasive diagnosis of ATTR-CA include pyrophosphate (99mTc-PYP); hydroxymethylene diphosphonate (99mTc-HMDP); and 3,3-diphosphono-1,2-propanodicarboxylate (99mTc-DPD). Although nuclear scintigraphy has transformed the contemporary diagnostic approach to ATTR-CA, a number of grey areas remains, including the mechanism for binding tracers to the infiltrated heart, differences in the kinetics and distribution of these radiotracers, differences in protocols of image acquisition worldwide, the clinical significance of extra-cardiac uptake, and the use of this technique for prognostic stratification, monitoring disease progression and assessing the response to disease-modifying treatments. This review will deal with the most relevant unmet needs and clinical questions concerning scintigraphy with bone tracers in ATTR-CA, providing expert opinions on possible future developments in the clinical application of these radiotracers in order to offer practical information for the interpretation of nuclear images by physicians involved in the care of patients with this ATTR-CA. Full article
(This article belongs to the Special Issue Best Practices for Cardiovascular Team-Based Care: Cardiac Heart Diseases (CHD) Clinical Conundrum)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop